Annexin Pharmaceuticals

Clinical trials sponsored by Annexin Pharmaceuticals, explained in plain language.

Annexin Pharmaceuticals ANNX NASDAQ STOCKHOLM

Biotech developing Annexin A5 for vascular diseases.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.

Trials to join now! 1

New drug ANXV shows promise for common eye diseases in early trial

Disease control Recruiting now

This study tests a new drug called ANXV in 12 adults with eye diseases from diabetes or blocked retinal veins. The main goal is to check if ANXV is safe and if it can improve vision or reduce the need for other treatments. Participants receive ANXV as a 30-minute infusion for 5 d…

Phase 2 • Sponsor: Annexin Pharmaceuticals AB • Aim: Disease control

Last updated Jun 27, 2026 08:01 UTC

Annexin Pharmaceuticals

New drug ANXV shows promise for common eye diseases in early trial